AI Readiness Assessment for Pharmaceuticals
In pharma, readiness means validation readiness. GxP requirements, FDA expectations, and the need for validated systems mean an AI tool cannot just work, it must be qualified, documented, and traceable. Before investing, you need to know whether your data, from clinical trials to pharmacovigilance to regulatory submissions, is structured and governed well enough to support AI, and whether your infrastructure can carry validation and audit trails. We assess your data, talent, and infrastructure against real use cases like evidence synthesis and safety signal detection, with GxP and submission integrity as the lens, so you invest only in AI that can survive an inspection.
AI Readiness Assessment, built for pharmaceuticals
We assess whether your trial, safety, and submission data is structured, traceable, and governed well enough to support AI under GxP expectations.
We score use cases like evidence synthesis, pharmacovigilance triage, and submission drafting on feasibility and on whether they can be validated.
We review your infrastructure for validation readiness: audit trails, version control, and the documented qualification an FDA inspection would expect.
We deliver a readiness score and a prioritized plan that flags which use cases can be qualified now and which need data or controls work first.
Where it pays off in pharmaceuticals
Evidence synthesis readiness
Assess whether your literature and study data can support AI-assisted evidence synthesis with traceable sources for every claim.
Pharmacovigilance check
Score whether safety data and case volumes can support AI-assisted signal detection and triage while keeping a validated audit trail.
Submission integrity audit
Assess where AI could support regulatory submissions without compromising the documentation and traceability the FDA expects.
Validation gap map
Map where your infrastructure falls short of validated-system requirements, and what closes the gap before any GxP-relevant build.
Pharma clients leave with a GxP-aware readiness baseline that separates validatable use cases from premature ones, avoiding the costly path of building AI that could never pass inspection.
Pharmaceuticals AI, answered
Yes, that is the core lens. We assess each use case not just on whether it works but on whether it can be qualified, documented, and traced under GxP. A use case that cannot be validated is flagged as not ready regardless of its appeal.
It can, in supporting roles, if the documentation and traceability hold. We assess where AI could assist drafting or evidence synthesis without compromising the integrity an FDA submission requires, and the plan keeps every AI-touched output traceable to source.
The assessment tells you directly. We evaluate whether your safety data and case volumes can support AI-assisted signal detection and triage while preserving a validated audit trail, and we prioritize the fixes if they are not yet there.
More Pharmaceuticals AI
AI Readiness Assessment for other industries
Bring AI Readiness Assessment to your pharmaceuticals team
Book a free consultation. We'll show you the highest-leverage place to start and exactly how we'd ship it.